Investigation of effect of nintedanib in experimental uveitis model

References

• Yalçındağ FN, Özdal PC, Özyazgan Y, et al. Demographic and clinical characteristics of Uveitis in Turkey: the first national registry report. Ocul Immunol Inflamm 2018;26:17–26.
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Talat L, Bar A, et al. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology 2014;121:387–392.
   PubMed Web of Science ®Google Scholar
• Jabs DA. Immunosuppression for the Uveitides. Ophthalmology 2018;125:193–202.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RR. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Yadav UCS, Ramana KV. Endotoxin-induced Uveitis in rodents. Methods Mol Biol 2019;1960:161–168.
   PubMedGoogle Scholar
• Franks WA, Limb GA, Standford MR, et al. Cytokines in human intraocular inflammation. Curr Eye Res 1992;11:187–191.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth G, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:774–782.
   Web of Science ®Google Scholar
• Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 2014;349:209–220.
   PubMed Web of Science ®Google Scholar
• Inomata M, Nishioka Y, Azuma A. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evid 2015;10:89–98.
   PubMed Web of Science ®Google Scholar
• Kudo K, Arao T, Tanaka K, et al. Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2 + pTyr + peripheral blood leukocytes as a pharmacodynamic biomarker in vivo. Clin Cancer Res 2011;17:373–381.
   Web of Science ®Google Scholar
• Keating GM. Nintedanib: a review of its use in patients with idiopathic pulmonary fibrosis. Drugs 2015;75:131–140.
   Web of Science ®Google Scholar
• Fala L. Ofev (Nintedanib): first tyrosine kinase inhibitor approved for the treatment of patients with idiopathic pulmonary fibrosis. Am Health Drug Benefits 2015;8:101–104.
   PubMedGoogle Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:071–082.
   Web of Science ®Google Scholar
• Kim HY, Kim MS, Kim SH, et al. Protective effects of nintedanib against polyhexamethylene guanidine phosphate-induced lung fibrosis in mice. Molecules 2018;23:1974.
   Web of Science ®Google Scholar
• Kong LY, Lai C, Wilson BC, et al. Protein tyrosine kinase inhibitors decrease lipopolysaccharide-induced proinflammatory cytokine production in mixed glia, microglia-enriched or astrocyte-enriched cultures. Neurochem Int 1997;30:491–497.
   PubMed Web of Science ®Google Scholar
• Lin T, Gong L. Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib. Drug Des Devel Ther 2017;11:147–158.
   Web of Science ®Google Scholar
• Caspi RR, Silver PB, Luger D, et al. Mouse models of experimental autoimmune uveitis. Ophthalmic Res 2008;40:169–174.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, McDevitt HO, Guss RB, et al. Endotoxin-induced uveitis in rats as a model for human disease. Nature 1980;286:611–613.
   PubMed Web of Science ®Google Scholar
• Behar-Cohen FF, Savoldelli M, Parel JM, et al. Reduction of corneal edema in endotoxin-induced uveitis after application of L-NAME as nitric oxide synthase inhibitor in rats by iontophoresis. Invest Ophthalmol Visual Sci 1998;39.6:897–904.
   Web of Science ®Google Scholar
• Tilton RG, Chang K, Corbett JA, et al. Endotoxin-induced uveitis in the rat is attenuated by inhibition of nitric oxide production. Invest Ophthalmol Vis Sci 1994;35:278–288.
   Web of Science ®Google Scholar
• Yao N, Lan F, He RR, et al. Protective effects of bilberry (Vaccinium myrtillus L.) extract against endotoxin-induced uveitis in mice. J Agric Food Chem 2010;58:731–736.
   Web of Science ®Google Scholar
• Lowry OH, Rosenbrough NJ, Farr AL. RR. Protein measurements with the Folin fenol reagent. J. Biol. Chem 1951;193:265–275.
   PubMed Web of Science ®Google Scholar
• De Vos AF, Klaren VN. Kijlstra Expression of multiple cytokines and IL-1RA in the uvea and retina during endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci 1994;35:873–883.
   Web of Science ®Google Scholar
• Okada AA, Sakai J, Usui M, et al. Intraocular cytokine quantification of experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998;6:111–120.
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-α in clinical uveitis. Ophthalmic Res 2001;33:251–255.
   PubMed Web of Science ®Google Scholar
• Lindstedt EW, Baarsma GS, Kuijpers RWAM, et al. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005;89:533–536.
   PubMed Web of Science ®Google Scholar
• Robertson M, Liversidge J, Forrester JV, et al. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2003;44:34–41.
   Web of Science ®Google Scholar
• Hoekzema R, Murray PI, Kijlstra A. Cytokines and intraocular inflammation. Curr Eye Res 1990;9:207–201.
   PubMed Web of Science ®Google Scholar
• Greiner K, Murphy CC, Willermain F, et al. Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci 2004;45:170–176.
   PubMed Web of Science ®Google Scholar
• Hoekzema R, Murray PI, van Haren MA, et al. Analysis of interleukin-6 in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci 1991;32:88–95.
   PubMed Web of Science ®Google Scholar
• Vos AFD, Hoekzema R, Kijlstra A. Cytokines and uveitis, a review. Curr Eye Res 1992;11:581–597.
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211–225.
   PubMed Web of Science ®Google Scholar
• Sun L, Tran N, Tang F, et al. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem 1998;41:588–603.
   Web of Science ®Google Scholar
• Guo K, Bu X, Yang C, et al. Treatment effects of the second-generation tyrosine kinase inhibitor dasatinib on autoimmune arthritis. Front Immunol 2019;9:3133.
   PubMed Web of Science ®Google Scholar
• Varone F, Sgalla G, Iovene B, et al. Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert Opin Pharmacother 2018;19:167–175.
   PubMed Web of Science ®Google Scholar
• Ogura T, Taniguchi H, Azuma A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 2015;45:208–210.
   Web of Science ®Google Scholar
• Turgut B, Gül FC, Dağli F, et al. Impact of ghrelin on vitreous cytokine levels in an experimental uveitis model. Drug Des Devel Ther 2013;7:19–24.
   PubMed Web of Science ®Google Scholar
• Gül FC, Turgut B, Dağlı F, et al. The comparison of the impact of ghrelin and tacrolimus on vitreous cytokine levels in an experimental uveitis model. Graefes Arch Clin Exp Ophthalmol 2013;251:235–241.
   PubMed Web of Science ®Google Scholar